Previous Page
20
nanotimes
Companies Facts
for rapid detection and grading of various multiple cancers using blood assays, with higher accuracy and at less cost than current single ELISA assays. All diagnostic and pharmaceutical products will inclu- de QMC quantum dots functionalized by Nanoaxis biomedical IP nanotechnology.
uantuMDx Group Limited has signed an exclusive license agreement with Nanosys
Inc., an advanced materials architect, for several patents and patent applications related to the use of nanostructures for biosensors. The core intellectual property involves the use of nanowires and nano- tubes in biosensors, including field effect transistors (FETs) biosensors, which were derived from the work of Prof. Charles Lieber, a professor of chemistry at Harvard and pioneer in nanotechnology.
Under terms of the agreement, QuantuMDx has secured exclusive worldwide rights for the use of nanostructures for DNA sequencing and, amongst others, detecting nucleic acid biomarkers associ- ated with disease. In exchange, Nanosys has recei- ved an upfront license fee and downstream royalty payments. No other financial details of the deal were disclosed.
QuantuMDx Group’s medical director, Professor Sir John Burn, went on to say “We are creating a simple to use, sample to result device which will provide ro- bust, handheld, clinical DNA sequencing at the point of care. The technology is cheap by any measure and with turnaround times in the minutes, it will be an exciting and significant new instrument in the clinical
Advertisement
Too fast for a photo: the new µsprint
11-09 :: September 2011
sec
Typical measurement system: >180 sec µsprint: 1 sec
NanoFocus AG Lindnerstrasse 98 | 46149 Oberhausen Phone +49 (0) 208-62 000-0 | Fax +49 (0) 208-62 000 info@nanofocus.de | www.nanofocus.de WKN: 540066 | ISIN: DE 0005400667
NF10030